Related references
Note: Only part of the references are listed.Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: Case series of 15 patients
Maria Pichler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review
Forum Patel et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Canakinumab in adults with steroid-refractory pyoderma gangrenosum
A. G. A. Kolios et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene
T. Zeeli et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2015)
Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts
Philipp Al Ghazal et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2015)
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial
Anthony D. Ormerod et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial
Anthony D. Ormerod et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum
S. Kapila et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2014)
Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome
A. V. Marzano et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis
Niels Teich et al.
JOURNAL OF CROHNS & COLITIS (2014)
Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease
F. Argueelles-Arias et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients
Philipp Al Ghazal et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Biological therapy for dermatological manifestations of inflammatory bowel disease
Maddalena Zippi et al.
WORLD JOURNAL OF CLINICAL CASES (2013)
Successful Treatment of Localized Pyoderma Gangrenosum with Topical Pimecrolimus
Roberto Cecchi et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2012)
Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab
Ari M. Goldminz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Adalimumab: a Treatment Option for Pyoderma Gangrenosum After Failure of Systemic Standard Therapies
Louisa Hinterberger et al.
DERMATOLOGY AND THERAPY (2012)
Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab
Emmanuella Guenova et al.
ARCHIVES OF DERMATOLOGY (2011)
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum A Case Series and Literature Review
Jennifer L. Hsiao et al.
ARCHIVES OF DERMATOLOGY (2010)
Pyoderma gangrenosum: A review and update on new therapies
Jeremiah Miller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study
Hewa Fonsekage Sanjeewani Fonseka et al.
INTERNATIONAL WOUND JOURNAL (2010)
Septic Shock after Treatment of Pyoderma Gangrenosum with Infliximab
Florian Woelbing et al.
ACTA DERMATO-VENEREOLOGICA (2009)
Pyoderma gangrenosum: an updated review
E. Ruocco et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Intravenous immunoglobulin for pyoderma gangrenosum
A. Kreuter et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Treatment of pyoderma gangrenosum with intravenous immunoglobulin
D. L. Cummins et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Use of infliximab in pyoderma gangrenosum
Daniel Hewitt et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2007)
An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum
Andrew P. Kontos et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2006)
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn et al.
GUT (2006)
Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients
J Reichrath et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder
CA Wise et al.
HUMAN MOLECULAR GENETICS (2002)
Topical tacrolimus in the management of peristomal pyoderma gangrenosum
CC Lyon et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2001)
Share Paper
